303 results on '"PECP - Centre for Pharmaceutical Policy and Regulation"'
Search Results
2. Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study
3. A blueprint for health technology assessment capacity building: lessons learned from Malta
4. A literature review of quality assessment and applicability to HTA of risk prediction models of coronary heart disease in patients with diabetes
5. Epidemiological surveillance of drug safety using cumulative sequential analysis in electronic healthcare data
6. Lifecycle HTA: Promising applications and a framework for implementation
7. The impact of scheduling ketamine as an internationally controlled substance on anaesthesia care in Sub-Saharan Africa: a case study and key informant interviews
8. Increasing uptake through collaboration in the development of core outcome sets: Lessons learned at OMERACT 2023
9. Outer packaging labelling of medicines in Southern African Development Community (SADC) countries: comparative analysis of requirements and transition terms for harmonisation
10. Importance of aligning the implementation of new payment models for innovative pharmaceuticals in European countries
11. Tools for assessing quality of studies investigating health interventions using real-world data: a literature review and content analysis
12. Adoption of new medicines in primary care: A comparison between the uptake of new oral anticoagulants and diabetes medicines
13. Uptake of orphan drugs in the WHO essential medicines lists
14. Trends in orphan medicinal products approvals in the European Union between 2010–2022
15. Evaluation of alignment of the reimbursement medicines list for children in Albania with the WHO essential medicines list for children
16. Monitoring Access to Child Medicines: Introducing a Standardized Set of Age-Appropriate Medicines
17. Disease severity-based subgrouping of type 2 diabetes does not parallel differences in quality of life: the Maastricht Study
18. High cost oncology drugs without proof of added benefit are burdening health systems
19. The caregiver’s experience of childhood cancer treatment in South Africa
20. Study in support of the evaluation and impact assessment of the EU general pharmaceuticals legislation: Analytical Report
21. Study in support of the evaluation and impact assessment of the EU general pharmaceuticals legislation: Evaluation Report
22. Traits, trends and hits of orphan drug designations in cystic fibrosis
23. Transforming pharmaceutical education: A needs-based global analysis for policy development
24. Medicine shortages: impact behind numbers
25. Alignment in the registration, selection, procurement and reimbursement of essential medicines for childhood cancers in South Africa
26. Marketing of medicines in primary care: An analysis of direct marketing mailings and advertisements
27. A systematic review of policies regulating or removing mark-ups in the pharmaceutical supply and distribution chain
28. Barriers to accessing internationally controlled essential medicines in sub-saharan Africa: A scoping review
29. Adverse Events to SARS-CoV-2 (COVID-19) Vaccines and Policy Considerations that Inform the Funding of Safety Surveillance in Low- and Middle-Income Countries: A Mixed Methods Study
30. Regulatory, health technology assessment and company interactions: the current landscape and future ecosystem for drug development, review and reimbursement
31. Duration of Effectiveness Evaluation of Additional Risk Minimisation Measures for Centrally Authorised Medicinal Products in the EU Between 2012 and 2021
32. Health technology assessment of tests for SARS-CoV-2 and treatments for COVID-19: A proposed approach and best-practice recommendations
33. Improved knowledge on substandard and falsified (SF) medical products through a dedicated course for pharmacy students at three universities in sub-Saharan Africa
34. Sustainable Development Goal indicator for measuring availability and affordability of medicines for children: a proof-of-concept study
35. Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment
36. The role of stakeholder involvement in the evolving EU HTA process: Insights generated through the European Access Academy's multi-stakeholder pre-convention questionnaire.
37. Impact of a Treatment Guide on Intravenous Fluids in Minimising the Risk of Hospital-Acquired Hyponatraemia in Denmark
38. Recommendations for patient involvement in health technology assessment in Central and Eastern European countries
39. Uncertainty management in regulatory and health technology assessment decision-making on drugs: guidance of the HTAi-DIA Working Group
40. Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts
41. Post-approval quality-related regulatory actions for biopharmaceuticals approved in the European Union and the United States between 1995 and 2019
42. Health technology assessment in Türkiye: Current status and perspectives on future implementation
43. SDG indicator 3.b.3 - an analysis of its robustness and challenges for measuring access to medicines for children
44. Pharmaceutical Scientists' Perspectives on Capacity Building in Pharmaceutical Sciences
45. The role of Real-World Data and evidence in oncology medicines approved in EU in 2018-2019
46. Regional Disparity in First-in-Class Anticancer Drug Development in the US, EU, and Japan
47. Synergy between health technology assessments and clinical guidelines for multiple sclerosis
48. Suspected adverse reactions reported for blood, blood components, and blood products in VigiBase
49. Guidance on using real-world evidence from Western Europe in Central and Eastern European health policy decision making
50. Reimbursement and payment models in Central and Eastern European as well as Middle Eastern countries: A survey of their current use and future outlook
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.